Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298233 | 0.93 | NPC1 (0.55) | NPC1RAB9AKCNK9NR1H4TRPV1 | |
| SCHEMBL2294478 | 0.91 | NPC1 (0.48) | NPC1RAB9AKCNK9MEN1KMT2A | |
| SCHEMBL2296935 | 0.91 | ALDH1A1 (0.46) | NPC1RAB9ANR1H4TRPV1MEN1 | |
| SCHEMBL2297422 | 0.90 | KMT2A (0.46) | NPC1RAB9AMEN1KMT2AACSS2 | |
| SCHEMBL2292564 | 0.90 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2AACSS2 | |
| SCHEMBL2299394 | 0.89 | F2 (0.44) | NPC1RAB9ANR1H4MEN1KMT2A | |
| SCHEMBL2299812 | 0.89 | NPC1 (0.45) | NPC1RAB9AMEN1KMT2AACSS2 | |
| SCHEMBL2292514 | 0.89 | RAB9A (0.47) | NPC1RAB9ATRPV1MEN1KMT2A | |
| SCHEMBL2297005 | 0.89 | MAPT (0.49) | NPC1RAB9ATRPV1MEN1KMT2A | |
| SCHEMBL2296047 | 0.89 | NPC1 (0.42) | NPC1RAB9AMEN1KMT2AACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | NPC1 2770/4885RAB9A 1893/4885KCNK9 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.